Kyle Rasbach - Chief Financial Officer at Lexeo Therapeutics, Inc.

Issuer-level insider activity

Role
Chief Financial Officer
Issuer ticker
LXEO on Nasdaq
Identity Names, identifiers, and filing context for this profile. 1 identity field
Entity type
Individual
Source evidence Original filing metadata and source links for verification. 1 source field
Source filing history
Open source filing history

No buys or sells have been reported by Kyle Rasbach since 14 Sep 2025

Reported holdings for Kyle Rasbach in Lexeo Therapeutics, Inc.

Form 4 holding Chief Financial Officer

Lexeo Therapeutics, Inc.

Security class
Common Stock
Shares / value
40,875
Estimated value
$335,032
Report date
17 Jan 2025
Price
$8.20
Ownership
Direct
Form 4 holding Chief Financial Officer

Lexeo Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
245,250
Estimated value
Report date
17 Jan 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Transaction history for Kyle Rasbach in Lexeo Therapeutics, Inc.

Sym Class Transaction % SEC-reported value SEC-reported price Shares Shares after Date Ownership
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .